When I came across the speaker list for New York City Inflammatory Bowel Disease (IBD) Research Day, I was pleased to see so many familiar names. In fact, a majority of the presenters are grantees or Scientific Advisory Board members at the Kenneth Rainin Foundation. These scientists are on the cutting-edge of their fields and I’m looking forward to hearing their fresh thinking.
This annual Research Day is sponsored by Icahn School of Medicine at Mount Sinai, The Rockefeller University and Weill Cornell Medicine. It’s an important platform for the field to share the high-risk ideas that will give us the best chance of discovering breakthroughs. And, New York City is an ideal location because it’s such an important hub for Inflammatory Bowel Disease research.
Complementing our Strategic Vision
This is the third year that the Rainin Foundation has supported the event. There are a number of reasons why this event is a strong complement to the Rainin Foundation’s vision of dramatically transforming the prediction and prevention of IBD. First, it has a focus on translational science and ways to bring science closer to the patient. Secondly, it’s very inclusive of trainees, and we’re committed to creating pipelines of researchers in IBD. And at the same time, much like our annual Innovations Symposium, it’s creating important research networks.
I hope to meet you there.
Bana Jabri, MD, PhD, University of Chicago
Iliyan Iliev, PhD, Weill Cornell Medicine
Julie Magarian Blander, PhD, Weill Cornell Medicine
Gérard Eberl, PhD, Institut Pasteur
Dana Philpott, PhD, University of Toronto
Saurabh Mehandru, MD, Mount Sinai
Megan Levings, PhD, BC Children’s Hospital Research Institute
Ruslan Medzhitov, PhD, Yale University
Icahn School of Medicine at Mount Sinai
The Rockefeller University
Weill Cornell Medicine
Laura Wilson, PhD
Director, Health Strategy & Ventures
Laura leads the strategic direction for the Foundation’s Health program by collaborating with leading scientific and medical researchers, as well as building partnerships with organizations and international stakeholders to expand and advance innovative Inflammatory Bowel Disease research. Read more.